How to buy Monopar Therapeutics stock | $4.58

Monopar Therapeutics Inc is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Monopar Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

Monopar Therapeutics stock price (NASDAQ: MNPR)

Use our graph to track the performance of MNPR stocks over time.

Monopar Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-24.

Latest market close	$4.58
52-week range	$4.28 - $10.55
50-day moving average	$4.94
200-day moving average	$5.35
Wall St. target price	$40.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.65

Buy Monopar Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Monopar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Monopar Therapeutics price performance over time

Historical closes compared with the close of $4.58 from 2021-10-22

1 week (2021-10-15)	-6.72%
1 month (2021-09-24)	-10.55%
3 months (2021-07-23)	-17.48%
6 months (2021-04-23)	-21.84%

1 year (2020-10-23)	-4.58%
2 years (2019-10-20)	N/A
3 years (2018-10-20)	N/A
5 years (2016-10-20)	N/A

Monopar Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-26.49%
Return on equity TTM	-43.55%
Profit margin	0%
Book value	$1.86
Market capitalisation	$57.6 million

TTM: trailing 12 months

Shorting Monopar Therapeutics shares

There are currently 80,464 Monopar Therapeutics shares held short by investors – that's known as Monopar Therapeutics's "short interest". This figure is 17.2% down from 97,168 last month.

There are a few different ways that this level of interest in shorting Monopar Therapeutics shares can be evaluated.

Monopar Therapeutics's "short interest ratio" (SIR)

Monopar Therapeutics's "short interest ratio" (SIR) is the quantity of Monopar Therapeutics shares currently shorted divided by the average quantity of Monopar Therapeutics shares traded daily (recently around 154738.46153846). Monopar Therapeutics's SIR currently stands at 0.52. In other words for every 100,000 Monopar Therapeutics shares traded daily on the market, roughly 520 shares are currently held short.

However Monopar Therapeutics's short interest can also be evaluated against the total number of Monopar Therapeutics shares, or, against the total number of tradable Monopar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Monopar Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Monopar Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0181% of the tradable shares (for every 100,000 tradable Monopar Therapeutics shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Monopar Therapeutics.

Find out more about how you can short Monopar Therapeutics stock.

Monopar Therapeutics share dividends

We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.

Monopar Therapeutics overview

Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Frequently asked questions

What percentage of Monopar Therapeutics is owned by insiders or institutions?
Currently 64.763% of Monopar Therapeutics shares are held by insiders and 1.484% by institutions. How many people work for Monopar Therapeutics?
Latest data suggests 9 work at Monopar Therapeutics. When does the fiscal year end for Monopar Therapeutics?
Monopar Therapeutics's fiscal year ends in December. Where is Monopar Therapeutics based?
Monopar Therapeutics's address is: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 What is Monopar Therapeutics's ISIN number?
Monopar Therapeutics's international securities identification number is: US61023L1089 What is Monopar Therapeutics's CUSIP number?
Monopar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61023L108